Response to: "Use of a prognostic gene expression profile test for T1 cutaneous melanoma: Will it help or harm patients?"

Affiliations

¹ Department of Plastic Surgery, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio.
² Castle Biosciences, Inc, Friendswood, Texas. Electronic address: rcook@castlebiosciences.com.

Comment

Brian R Gastman et al. J Am Acad Dermatol. 2019 Jun.

. 2019 Jun;80(6):e163-e164.

doi: 10.1016/j.jaad.2018.12.032. Epub 2018 Dec 23.

¹ Department of Plastic Surgery, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio.
² Castle Biosciences, Inc, Friendswood, Texas. Electronic address: rcook@castlebiosciences.com.

No abstract available

Comment on

Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria.
Gastman BR, Gerami P, Kurley SJ, Cook RW, Leachman S, Vetto JT. Gastman BR, et al. J Am Acad Dermatol. 2019 Jan;80(1):149-157.e4. doi: 10.1016/j.jaad.2018.07.028. Epub 2018 Aug 4. J Am Acad Dermatol. 2019. PMID: 30081113
Use of a prognostic gene expression profile test for T1 cutaneous melanoma: Will it help or harm patients?
Marchetti MA, Bartlett EK, Dusza SW, Bichakjian CK. Marchetti MA, et al. J Am Acad Dermatol. 2019 Jun;80(6):e161-e162. doi: 10.1016/j.jaad.2018.11.063. Epub 2018 Dec 23. J Am Acad Dermatol. 2019. PMID: 30586612 No abstract available.